REFRACTORY MYELODYSPLASTIC SYNDROME
Clinical trials for REFRACTORY MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for REFRACTORY MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis study tests a combination of two drugs, venetoclax and azacitidine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has returned or not responded to standard therapy. The goal is to find the best dose and see how well th…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:43 UTC
-
Experimental drug TAK-243 takes on tough blood cancers
Disease control TerminatedThis early-stage trial tests a new drug called TAK-243 in about 42 adults whose acute myeloid leukemia or myelodysplastic syndrome has returned or stopped responding to standard therapy. The main goals are to find the best dose and check for side effects. TAK-243 works by blockin…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
New drug cocktail targets Hard-to-Treat leukemia
Disease control TerminatedThis early-stage trial tested whether adding regorafenib to the standard venetoclax and azacitidine regimen is safe and effective for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The study aimed to find the best dose and check fo…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 04:29 UTC
-
New hope for tough blood cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called olaparib in 14 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to treatment, and who have a specific change in the IDH gene. The drug works by blocking enzymes that cancer cells need to g…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Experimental combo offers hope for tough blood cancers
Disease control OngoingThis early-stage study tests a combination of two drugs—ipilimumab, which boosts the immune system to attack cancer, and decitabine, a chemotherapy drug—in people whose myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has returned or not responded to prior treatment…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
New hope for kids with relapsed leukemia: drug combo targets hidden cancer cells
Disease control OngoingThis early-phase trial tests a new drug called uproleselan combined with standard chemotherapy (fludarabine and cytarabine) in children and teens with acute myeloid leukemia, myelodysplastic syndrome, or mixed phenotype acute leukemia that has returned or not responded to treatme…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug hunts and kills stubborn bone marrow cancer cells
Disease control TerminatedThis early-stage trial tests a new drug called lintuzumab-Ac225 for people with a high-risk type of myelodysplastic syndrome (MDS) that did not get better with standard treatments. The drug works like a smart bomb: it attaches to cancer cells and delivers a small dose of radiatio…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:38 UTC